ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1

Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand

(2017) Tanin Intragumtornchai et al.   HEMATOLOGICAL ONCOLOGY

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

(2016) Grzegorz S Nowakowski et al.   Future Oncology

State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma

(2016) Annalisa Chiappella et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

(2016) Michael Crump et al.   JOURNAL OF CLINICAL ONCOLOGY

A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma

(2016) Xueying Li et al.   Oncotarget

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

(2015) John D. Hainsworth et al.   LEUKEMIA & LYMPHOMA

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

(2015) Rosalba Camicia et al.   Molecular Cancer

A central role for TRPS1 in the control of cell cycle and cancer development

(2015) Lele Wu et al.   Oncotarget

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2014) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer

(2013) J. Q. Chen et al.   ANNALS OF ONCOLOGY

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Diffuse large B cell lymphoma: molecular targeted therapy

(2012) Mark Roschewski et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

(2011) Teri N. Kreisl et al.   NEURO-ONCOLOGY

Enzastaurin, a Protein Kinase C  Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells

(2008) K.-W. Lee et al.   CANCER RESEARCH